The Guidance Document for the Costing of Health Care Resources in the Canadian Setting: Second Edition is intended to guide researchers to publicly available cost information and to encourage transparency in the use of costs in economic evaluations for Canada. It replaces the Canada's Drug Agency A Guidance Document for the Costing Process (1996).
The Canadian Agency for Drugs and Technologies in Health (CADTH) examined the clinical and economic impact of new and existing drugs to treat pulmonary arterial hypertension (PAH).
The review included drugs that are currently available in Canada, and those that are newly emerging and not yet approved in Canada.
The project had two key components:
The Canadian Agency for Drugs and Technologies in Health (CADTH) has examined the comparative efficacy and safety of drug therapies for relapsing-remitting multiple sclerosis (RRMS).
The review included drugs that are currently available in Canada, and those that are newly emerging and not yet approved in Canada.
The project comprised several key components:
In combination with lifestyle measures (weight control, proper nutrition, and adequate exercise), medications, such as metformin and sulfonylureas, play an important role in achieving glycemic control in patients with diabetes mellitus:
The Canadian Agency for Drugs and Technologies in Health (CADTH) developed the following tools to help transition our recommendations from paper into practice.
To make these tools relevant to different audiences, Canada's Drug Agency can tailor specific tools to individual needs and settings. Contact us if you would like our assistance in tailoring any of these tools to meet your unique needs as a health care provider, policy-maker, or consumer.
An amendment to this report to reflect the inclusion of additional portable monitoring devices that are licensed in Canada has been made. The revised report is now available.
Health care decision-makers and health care professionals need efficient access to the best evidence. Health technology assessment agencies and guideline developers need access to evidence from economic evaluations to identify the cost-effectiveness of a technology and to inform economic models.
The English language is generally perceived to be the universal language of science.1,2 The top 10 international medical journals in 11 medical specialties (measured by impact factor) are English-language publications.3 The exclusive reliance, however, on data that are published in English and that are used as the basis of systematic reviews of health care interventions may not result in an accurate representation of existing evidence. Excluding languages other than English (LOE) may lead to erroneous conclusions, because a language bias is introduced.
The four-part Canada's Drug Agency health technology assessment series on Canadian emergency department (ED) overcrowding is the first national, comprehensive study of the issue. It is designed to help Canadian policy makers, hospital and ED administrators, and health care researchers better understand the nature of ED overcrowding and what they can do about it. The reports look at: